Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral,… Read more
Pliant Therapeutics Inc (PLRX) - Total Liabilities
Latest total liabilities as of September 2025: $76.29 Million USD
Based on the latest financial reports, Pliant Therapeutics Inc (PLRX) has total liabilities worth $76.29 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pliant Therapeutics Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Pliant Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pliant Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Pliant Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Berjaya Corporation Berhad
PINK:BRYAF
|
USA | $13.59 Billion |
|
Gyldendal A/S
CO:GYLD-B
|
Denmark | Dkr290.27 Million |
|
Bosch Home Comfort India Limited
NSE:BOSCH-HCIL
|
India | ₹7.29 Billion |
|
Global Lights Acquisition Corp Ordinary Shares
NASDAQ:GLAC
|
USA | $2.99 Million |
|
Lassila &Tikanoja Oyj
HE:LAT1V
|
Finland | €413.00 Million |
|
Bhiraj Office Leasehold Real Estate Investment Trust
BK:BOFFICE
|
Thailand | ฿2.56 Billion |
|
ReproCELL Incorporated
F:6RC
|
Germany | €688.22 Million |
|
Kernel Holding SA
F:0KE
|
Germany | €1.23 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Pliant Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pliant Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pliant Therapeutics Inc (2017–2024)
The table below shows the annual total liabilities of Pliant Therapeutics Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $92.87 Million | +140.73% |
| 2023-12-31 | $38.58 Million | +3.51% |
| 2022-12-31 | $37.27 Million | +68.22% |
| 2021-12-31 | $22.16 Million | +77.75% |
| 2020-12-31 | $12.46 Million | -89.57% |
| 2019-12-31 | $119.50 Million | +77.27% |
| 2018-12-31 | $67.41 Million | +2014.52% |
| 2017-12-31 | $3.19 Million | -- |